OpGen Reports Second Quarter 2022 Financial Results and Provides Business Update

Rhea-AI Summary

OpGen reported total Q2 2022 revenues of approximately $1.0 million, up from $0.8 million in Q2 2021. For the first half of 2022, revenues were about $1.4 million, compared to $1.6 million in H1 2021. Operating expenses decreased to approximately $6.2 million in Q2 2022 from $7.0 million a year prior. The net loss for Q2 2022 was $5.8 million, or $0.13 per share. The company signed contracts for its Acuitas AMR Gene Panel and is progressing on its Unyvero UTI Panel clinical trial with 1,300 samples enrolled, targeting 1,500.

Positive

• Revenue growth: Total revenue increased to $1.0 million in Q2 2022, compared to $0.8 million in Q2 2021.
• Successful contracts: Signed first two commercial contracts for Acuitas AMR Gene Panel with major hospitals.
• R&D progress: Added a fourth trial site for Unyvero UTI Panel, nearing 1,500 patient samples enrollment.

Negative

• Net loss: Second quarter net loss was $5.8 million, compared to $7.1 million a year ago, indicating ongoing financial strain.
• Cash decline: Cash and cash equivalents decreased to $16.6 million from $36.1 million since December 2021.
• Compliance concerns: Requested a 180-day extension from Nasdaq to regain compliance with minimum bid price rule.

• Total Q2 2022 revenues of $1.0 million with product sales a key growth driver
• First two commercial customer contracts for Acuitas AMR Gene Panel signed in June and July 2022
• Requested additional 180-day period to regain compliance with Nasdaq minimum bid price rule
• Management conference call scheduled for August 11^th, 2022, at 4:30 p.m. EDT

ROCKVILLE, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter 2022 financial and operating results. Management will host an investor call to discuss quarterly results and provide a business update.

Oliver Schacht, President & CEO of OpGen, commented, “We are pleased with the progress we’ve made in the first half of 2022, which includes signing two commercial contracts for our Acuitas AMR Gene Panel with two major U.S. hospitals. Additionally, we have added a fourth trial site and continued enrollment towards our 1,500^th patient sample for the clinical trial for Unyvero Urinary Tract Infection (UTI) Panel. We anticipate completing the enrollment and expect final data read out in the second half of this year towards an FDA submission.”

Dr. Schacht continued, “Overall we are tracking well against our R&D milestones and continue to progress on the commercial front with significant growth in direct product sales year over year. We look forward to continuing to update on our progress and continue the fight against antimicrobial resistance.”

Second Quarter and First Half 2022 Financial Results of OpGen, Inc.

• Total revenue for the second quarter of 2022 was approximately $1.0 million, compared with approximately $0.8 million in the second quarter of 2021. Total revenue for the first half of 2022 was approximately $1.4 million, as compared to approximately $1.6 million for the first half of 2021.        
• Operating expenses for the second quarter of 2022 were approximately $6.2 million, compared with approximately $7.0 million in the second quarter of 2021. Operating expenses for the first half of 2022 were approximately $12.6 million, compared with approximately $14.0 million in the first half of 2021.
• The net loss available to common stockholders for the second quarter of 2022 was approximately $5.8 million, or $0.13 per share, compared with approximately $7.1 million, or $0.19 per share, in the second quarter of 2021. The net loss available to common stockholders for the first half of 2022 was approximately $12.6 million, or $0.27 per share, compared with approximately $21.9 million, or $0.65 per share, in the first half of 2021.
• Cash and cash equivalents were approximately $16.6 million as of June 30, 2022, compared with $36.1 million as of December 31, 2021.

In the reporting quarter and year to date, the Company reached the following key milestones:

• OpGen signed its first two commercial customer contracts for the Acuitas AMR Gene Panel in June and July 2022 with a major 1,000+ bed teaching hospital in the Northeast and a renowned 400+ bed children’s hospital in the Midwest
• OpGen subsidiary Ares Genetics extended its collaboration agreement with Sandoz until 2025, to drive cutting-edge digital solutions in the global fight against antimicrobial resistance (AMR)
• OpGen subsidiary Ares Genetics also commercially launched new sequencing and analysis services globally, which includes ARESid and ARESiss Express
• OpGen announced interim analysis results from its clinical trial for Unyvero UTI Panel and added a fourth trial site
• OpGen to date has enrolled over 1,300 patient samples in the clinical trial for Unyvero UTI Panel and is on track towards the enrollment goal of 1,500 prospective patient samples
• OpGen subsidiary Curetis and Leader Life Sciences entered into a Unyvero distribution partnership within the United Arab Emirates and Qatar for a total value of approximately $1 million in revenue during the initial three-year term
• OpGen subsidiary Curetis and Keis Group entered into a three-year exclusive Unyvero distribution partnership in Kosovo based on Keis’ successfully won tender for Unyvero products
• OpGen and Menarini expanded their distribution agreement to increase the annual minimum revenue commitment by Menarini in the next two years, in addition to the sale of around 70 installed Unyvero systems across nine European countries at residual fair market value from OpGen’s subsidiary Curetis to Menarini
• OpGen announced publication of results from a major prospective, multi center, randomized and interventional clinical study using Unyvero Hospitalized Pneumonia (HPN) Panel in The Lancet Respiratory Medicine that demonstrated Unyvero decreases the duration of inappropriate antibiotic therapy in hospitalized patients with pneumonia
• OpGen announced publication of results of Unyvero HPN Panel for detection of bacterial respiratory tract pathogens from serial specimens collected from hospitalized COVID-19 patients at Karolinska University Hospital (Sweden), confirming the ability of Unyvero in detecting potential pneumonia pathogens earlier than culture
• OpGen commenced a new At The Market (ATM) sales facility for up to approximately $10.7 million, pursuant to which the Company may sell, from time to time, in an “at the market” offering shares of its common stock. While no shares were sold under this new ATM in H1 2022, in July and August to date the Company has sold approximately 1.7 million new shares of its common stock for gross proceeds of approximately $1 million.
• OpGen requested an additional 180-day period from Nasdaq to regain compliance with the $1.00 minimum bid price rule and expects their decision by the end of August.

In terms of fiscal 2022 guidance, OpGen expects:

• U.S. direct product sales of Unyvero and Acuitas are anticipated to contribute to growth
• Continuous increase in its European and international distribution business for Unyvero products
• Expand Ares Genetics strategic collaborations and partnerships and launch U.S. Next Generation Sequencing lab services in Q3 2022
• Overall, 2022 revenue growth of approximately 25% year over year from the products and services business globally

Conference Call Information

OpGen’s management will host a conference call today, August 11^th at 4:30 p.m. EDT, to go over the second quarter and first half of 2022 financial results and business activities, as well as answer analyst questions.

Dial-in Information

U.S. Dial-in Number: +1-877-704-4453

International Dial-in Number: +1-201-389-0920

Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1556114&tp_key=e1546ec0f5

Conference ID: 13730742

Following the conclusion of the conference call, a replay will be available through August 25^th, 2022. The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Company’s website at www.opgen.com.

A replay of the webcast will be available following the conclusion of the call and will be archived on the Company’s website for 90 days. Replay access information is below:

Replay Information

U.S. Dial-in Number: +1-844-512-2921

International Dial-in Number: +1-412-317-6671

Replay PIN: 13730742

About OpGen, Inc. OpGen, Inc. (Rockville, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s product portfolio includes Unyvero®, Acuitas® AMR Gene Panel and the ARES Technology Platform including ARESdb®, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.

For more information, please visit www.opgen.com.

Forward-Looking Statements

This press release includes statements regarding the second quarter and first half 2022 financials of OpGen and the current business of OpGen. These statements and other statements regarding OpGen’s future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, the success of our commercialization efforts, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the fact that we may not effectively use proceeds from recent financings, the continued realization of expected benefits of our business combination transaction with Curetis GmbH, the continued impact of COVID-19 on the Company’s operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, our ability to satisfy debt obligations under our loan with the European Investment Bank, the effect of the military action in Russia and Ukraine on our distributors, collaborators and service providers, our liquidity and working capital requirements, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

OpGen, Inc.
Consolidated Balance Sheets
(unaudited)
		June 30, 2022				December 31, 2021
Assets
Current assets
Cash and cash equivalents		$	16,586,577			$	36,080,392
Accounts receivable, net			738,148				1,172,396
Inventory, net			1,196,956				1,239,456
Prepaid expenses and other current assets			1,687,564				1,250,331
Total current assets			20,209,245				39,742,575
Property and equipment, net			3,209,311				4,011,748
Finance lease right-of-use assets, net			19,660				90,467
Operating lease right-of-use assets			1,582,325				1,814,396
Goodwill			6,884,915				7,453,007
Intangible assets, net			12,969,215				14,530,209
Strategic inventory			3,492,602				3,472,337
Other noncurrent assets			441,320				551,794
Total assets		$	48,808,593			$	71,666,533
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable		$	731,845			$	1,307,081
Accrued compensation and benefits			1,575,299				1,621,788
Accrued liabilities			788,153				1,965,845
Current maturities of long-term debt			10,887,469				14,519,113
Short-term finance lease liabilities			16,731				43,150
Short-term operating lease liabilities			394,027				459,792
Total current liabilities			14,393,524				19,916,769
Long-term debt, net			4,024,413				7,176,251
Derivative liabilities			175,498				228,589
Long-term finance lease liabilities			1,962				3,644
Long-term operating lease liabilities			2,721,233				2,977,402
Other long-term liabilities			130,983				146,798
Total liabilities			21,447,613				30,449,453
Stockholders' equity
Preferred stock, $0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2022 and December 31, 2021, respectively			—				—
Common stock, $0.01 par value; 100,000,000 shares authorized; 46,623,618 and 46,450,250 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively			466,237				464,503
Additional paid-in capital			276,205,778				275,708,490
Accumulated deficit			(248,185,670	)			(235,541,539	)
Accumulated other comprehensive (loss)/income			(1,125,365	)			585,626
Total stockholders’ equity			27,360,980				41,217,080
Total liabilities and stockholders’ equity		$	48,808,593			$	71,666,533

OpGen, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(unaudited)
		Three Months Ended June 30,								Six Months Ended June 30,
			2022				2021				2022				2021
Revenue
Product sales		$	889,271			$	307,804			$	1,255,323			$	835,383
Laboratory services			20,570				266,784				63,499				450,849
Collaboration revenue			57,364				237,027				118,128				355,099
Total revenue			967,205				811,615				1,436,950				1,641,331
Operating expenses
Cost of products sold			646,389				342,580				938,386				896,634
Cost of services			15,650				137,934				46,212				242,918
Research and development, net			2,273,756				2,859,590				4,590,197				5,673,081
General and administrative			2,134,266				2,692,255				4,759,319				5,355,912
Sales and marketing			1,169,349				802,549				2,220,781				1,701,801
Impairment of right-of-use asset			—				115,218				—				170,714
Total operating expenses			6,239,410				6,950,126				12,554,895				14,041,060
Operating loss			(5,272,205	)			(6,138,511	)			(11,117,945	)			(12,399,729	)
Other expense
Gain on extinguishment of debt			—				259,353				—				259,353
Warrant inducement expense			—				—				—				(7,755,541	)
Interest and other income, net			13,851				4,702				16,972				9,627
Interest expense			(779,912	)			(1,198,169	)			(2,049,493	)			(2,363,151	)
Foreign currency transaction gains/(losses)			271,967				(915	)			470,707				426,700
Change in fair value of derivative financial instruments			(74,116	)			(13,021	)			35,628				(114,411	)
Total other expense			(568,210	)			(948,050	)			(1,526,186	)			(9,537,423	)
Loss before income taxes			(5,840,415	)			(7,086,561	)			(12,644,131	)			(21,937,152	)
Provision for income taxes			—				—				—				—
Net loss		$	(5,840,415	)		$	(7,086,561	)		$	(12,644,131	)		$	(21,937,152	)
Net loss available to common stockholders		$	(5,840,415	)		$	(7,086,561	)		$	(12,644,131	)		$	(21,937,152	)
Basic and diluted net loss per share attributable to common stockholders		$	(0.13	)		$	(0.19	)		$	(0.27	)		$	(0.65	)
Weighted average shares outstanding - basic and diluted			46,574,512				38,268,293				46,529,718				33,900,964
Net loss		$	(5,840,415	)		$	(7,086,561	)		$	(12,644,131	)		$	(21,937,152	)
Other comprehensive loss - foreign currency translation			(1,227,142	)			529,651				(1,710,991	)			(548,828	)
Comprehensive loss		$	(7,067,557	)		$	(6,556,910	)		$	(14,355,122	)		$	(22,485,980	)

 

OpGen:
Oliver Schacht
President and CEO
InvestorRelations@opgen.com

OpGen Press Contact:
Matthew Bretzius 
FischTank Marketing and PR
matt@fischtankpr.com

OpGen Investor Contact:
Alyssa Factor
Edison Group
afactor@edisongroup.com

 

FAQ

What were OpGen's total revenues for Q2 2022?

OpGen reported total revenues of approximately $1.0 million for Q2 2022.

How much did OpGen's net loss amount to in Q2 2022?

The net loss available to common stockholders for Q2 2022 was approximately $5.8 million.

What developments did OpGen announce regarding the Acuitas AMR Gene Panel?

OpGen signed its first two commercial contracts for the Acuitas AMR Gene Panel in June and July 2022.

What is OpGen's guidance for revenue growth in 2022?

OpGen anticipates approximately 25% year-over-year revenue growth for its products and services in 2022.

What is the status of OpGen's compliance with Nasdaq rules?

OpGen requested an additional 180-day period from Nasdaq to regain compliance with the $1.00 minimum bid price rule.